Mclazide Plus M 80mg/500mg Tablet is a combination oral antidiabetic medication containing Gliclazide 80mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Gliclazide, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glycemic control. This dual mechanism addresses both insulin deficiency and insulin resistance, making Mclazide Plus M effective in patients inadequately controlled by diet and exercise alone. The tablet is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Common side effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often diminish with continued use. Caution is advised in patients with renal or hepatic impairment, and contraindications include diabetic ketoacidosis and severe renal dysfunction. Regular monitoring of renal function and hematological parameters is recommended during therapy. Mclazide Plus M should be used under medical supervision to optimize glycemic control and minimize potential adverse effects.